Affinity maturation and characterization of internalized human anti-Met recombinant antibody fab

Progress in Biochemistry and Biophysics

Volumn 34, Issue 1, 2007, Pages 73-79

  Zhu, Jin ^a,c   Zhao, Ping ^a,b   Jiao, Yong Jun ^a   Wang, Xin ^a   Cao, Bo Liang ^a,b   Feng, Zhen Qing ^a   Guan, Xiao Hong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c Huadong Medical Institute of Biotechniques   (China)

Author keywords

Affinity maturation; Hepatocyte growth factor receptor (Met); Internalized antibody; Phage displayed antibody library

Indexed keywords

EID: 34248562940     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinase as tagets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther, 2002, 93 (2-3): 79-98
2. Shawver L K, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer th erapy. Cancer cell, 2002, 1 (2): 117-123
3. Ciardiello F, Tortora G. A novle approach in the treatment of cancer: targeting the epidermal grouth factor receptor. Clin Cancer Res, 2001, 7 (10): 2958-2970
4. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci, 2003, 94 (4): 321-327
5. Cao B, Su Y L, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA, 2001, 98 (13): 7443-7448
6. Borowiak M. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA, 2004, 101 (29): 10608-10613
7. Popkov M, Jendreyko N, McGavem D B, et al. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res, 2005, 65 (3): 972-981
8. Rothlisberger D, Honegger A, Pluchthun A. Domain interaction in the fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol, 2005, 347(4): 773-789
9. Beatty J D, Beatty B G, Vlahos W G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods, 1987, 100 (1): 173-179
10. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-Met receptor in the migration of myogenic precursor cells into the limb bud. Nature, 1995, 373 (6543): 768-771
11. Shinomiya N, Vande Woude G F. Suppression of Met expression: a possible cancer treatment. Clin Cancer Res, 2003, 9(14): 5085-5090
12. Zhang Y W, Vande Woude G F. HGF/SF-Met signaling in the control of branching morphogenesis and invasion. J Cell Biochem, 2003, 88 (2): 408-417
13. Souriau C, Rothacker J, Henner R, et al. Human antibody fragments specific for epidermal growth factor receptor selected from large non-immunised phage display libraries. Growth Factor, 2004, 22 (3): 185-194
14. Leclerc E, Liemann S, Wildegger G, et al. Selection and characterization of single chain Fv fragments against murine recombinant prion protein from a synthetic human antibody phage display library. Hum Antibodies, 2000, 9 (4): 207-214
15. Weiner L M, Carter P. Tunable antibodies. Nature Biotech, 2005, 23 (5): 556-557
16. Osdol W, Fujimori K, Weinstein J N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier" . Cancer Res, 1991, 51(18): 4776-4784
17. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer, 2001, 1 (2): 118-129
18. Gura T. Therapeutic antibodies: magic bullets hit the target. Nature, 2002, 417 (6889): 584-586